ReviewNature reviews. Urology2019
Nonsurgical management of Peyronie's disease.
Review in Nature reviews. Urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Efficacy and Safety of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: An Evidence-Based Analysis.Frontiers in medicine · 2022Pooled it
- Phenotype-directed endpoints for nonsurgical Peyronie's disease management.Translational andrology and urology · 2026Article
- Peyronie's disease in Spain: a prospective study.Sexual medicine · 2026Article
- Current status of non-surgical treatments for Peyronie's disease.Translational andrology and urology · 2026Article
- Article
- A novel autologous material for the surgical treatment of Peyronie's disease: the outer plate of the prepuce.Translational andrology and urology · 2025Article
- Current and Future Directions of Technology in Assessment of Peyronie's Disease.Current urology reports · 2024Review
- Is there a new role for oral therapy to treat peyronie's disease? Commentary on Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's Disease: a retrospective comparative analysis.International journal of impotence research · 2024Article
- Measurement of Oxidative Stress Index (OSI) in Penile Corpora Cavernosa and Peripheral Blood of Peyronie's Disease Patients: A Report of 49 Cases.Metabolites · 2024Article
- The Application of Hyaluronic Acid Injections in Functional and Aesthetic Andrology: A Narrative Review.Gels (Basel, Switzerland) · 2023Review
- The collagenase of the bacterium Clostridium histolyticum does not favor metastasis of breast cancer.Breast cancer (Tokyo, Japan) · 2022Article
- The efficacy and safety of intralesional injection of collagenaseFrontiers in pharmacology · 2022Review
- Collagenase clostridium histolyticum is no longer available in Europe: what does this mean for our patients with Peyronie's Disease?International journal of impotence research · 2021Article
- Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.Current urology reports · 2021Review
- Long-term patient-reported outcomes in men with Peyronie's disease undergoing nonsurgical and nonintralesional injection management.International journal of impotence research · 2021Article
- Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.Frontiers in pharmacology · 2021Review
- Evolving therapies for Peyronie's disease: how can we work towards new drugs?Translational andrology and urology · 2020Review
- Minimally invasive therapies for Peyronie's disease: the current state of the art.Translational andrology and urology · 2020Review
- Clinical characteristics and surgical outcomes in men undergoing tunica albuginea plication for congenital penile curvature who present with worsening penile deformity.World journal of urology · 2020Article
- Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond.World journal of urology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peyronie's disease is not a rare disorder, and it can be devastating to the affected man. Although the gold-standard treatment of Peyronie's disease is surgery in the stable phase, nonoperative management is preferred by some men and is the only treatment option in the acute phase of the disease, when surgery is contraindicated. No oral or topical therapy has been shown to be efficacious when administered alone, but some evidence supports their use as part of a combination therapy regimen. Intralesional therapies, particularly collagenase clostridium histolyticum (CCH), have shown promise. Mechanical therapies can provide benefit when applied for prolonged periods of time, improving penile curvature, indentation, and even restoring length. Regardless of the modality chosen, patient counselling is paramount, as recovery of the penis to its predisease state is highly unlikely. Thus, although many options exist for nonsurgical management of Peyronie's disease, surgery remains the best option for men who desire the most reliable and rapid pathway to a functionally straight, erect penis. The goal of nonsurgical therapy should be a scientifically feasible, safe approach to prevent the progression of, or reduce, deformity and improve sexual function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.